Company intelligence / Profile preview
Thera Neuropharma
Berwyn, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Thera Neuropharma’s preclinical candidates have demonstrated neuroprotective and regenerative effects in animal models of ALS, improving neuronal survival, axonal regeneration, and delaying disease progression. sd-rxRNA SOD1 gene silencing and small molecule activation of NF-κB/MnSOD pathways show synergistic potential for disease modification in ALS.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeRNA therapySmall interfering RNA
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
RXi PharmaceuticalsSouthern ResearchVlaams Instituut voor Biotechnologie (Belgium)
Beyond the preview
Go deeper on Thera Neuropharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thera Neuropharma.